Insulet's RADIANT trial shows improved glycemic control with Omnipod 5 transition

From Nasdaq: 2025-03-19 21:58:27

Insulet Corp.’s RADIANT trial showed significant glycemic improvements with the Omnipod 5 Automated Insulin Delivery System, transitioning from multiple daily injections. The study was the first to evaluate this transition in adults and children with type 1 diabetes, using an AID system with an Abbott FreeStyle Libre 2 sensor. Participants saw an average HbA1c improvement of 0.8% after three months, reaching a final level of 7.2%. Users also spent 5.4 more hours per day in the target glucose range, with no life-threatening events reported. Lowering HbA1c levels can reduce the risk of complications like cardiovascular disease and kidney problems.



Read more at Nasdaq: Insulet’s RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition